PRGO up +0.47% percent Today $PRGO High is at 155.56 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
PRGO up +0.47% percent Today $PRGO High is at 155.56 and the Low 152.97 with current volume of 196,052.

Recent News posted below.

Perrigo Company PRGO other info.
http://investorshangout.com/Perrigo-Company-PRGO-55158/

PRGO Perrigo Company Recent Headline News

Survey Finds Infant Feeding Tops List of Questions New Parents Ask Pediatricians
PR Newswire - Thu Nov 13, 7:50AM CST
New parents often have an endless list of questions about caring for their little ones, and the pediatrician serves as a go-to resource for everything from nutritional needs to serving as a sounding board for surreal questions (Is it Okay to Take My Newborn Kite Surfing?), according to a new survey. Perrigo Nutritionals, makers of Store Brand Formula, today released findings from its nationwide "Pulse of Pediatricians" survey*--conducted by SERMO, the largest online network exclusively for physicians--and found that pediatricians rank feeding (52 percent), pooping (43 percent), and sleeping (41 percent) as the top three categories of concern for new parents. In fact, 97 percent of pediatricians say questions around feeding falls in the top three for their patients.
PRGO: 154.25 (-0.21)

Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST

WDFC: 76.29 (+0.01), SJR: 26.89 (+0.07), PRGO: 154.25 (-0.21), XYL: 37.57 (-0.05), CHRW: 72.82 (-0.25), MDLZ: 38.24 (+0.08), MKC: 72.52 (-0.02), MDU: 25.07 (-0.02), SYY: 38.89 (+0.31), PDCO: 46.08 (+0.84), PNR: 68.91 (+0.25), TRI: 38.58 (+0.15), UPS: 106.52 (-0.31), PEP: 98.16 (+0.44), AGN: 209.77 (+11.12), MSI: 65.20 (-0.05), NOV: 71.60 (+0.26), NWN: 46.34 (+0.21), EGN: 65.82 (-2.14), EBAY: 54.64 (+0.28), QCOM: 70.66 (-0.19), AMAT: 22.47 (-0.35), ACN: 84.56 (-0.08), AAPL: 113.89 (-0.29), MA: 83.48 (-0.57), SCHW: 28.49 (-0.38), STR: 23.41 (+0.04), SE: 38.43 (+0.31), GAS: 51.96 (+0.51), IRM: 37.90 (+0.21), WM: 49.15 (+0.06), CMP: 89.04 (+0.21), VRSK: 63.03 (+0.16), GILD: 100.57 (-1.49), EXPD: 43.73 (-0.19), TFX: 115.57 (+0.74), CVS: 89.58 (+0.45), PG: 87.73 (-0.38), PX: 126.12 (+0.26), NVS: 94.46 (+0.51)

Dividend Contenders, Future Champions Or Future Failures: Part 6
Stan Stafford - at Seeking Alpha - Fri Nov 07, 5:13PM CST

PRGO: 154.25 (-0.21), NVO: 43.71 (-0.42), CAH: 80.19 (-0.16), TEVA: 57.60 (+0.53)

Perrigo to re-launch the expectorant tablets Guaifenesin Extended-Release 600mg in the US
M2 - Fri Nov 07, 6:22AM CST
Healthcare company Perrigo Company (NYSE RGO) said on Thursday that it has re-initiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the US.
PRGO: 154.25 (-0.21)

Perrigo Public Limited's (PRGO) CEO Joseph Papa on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 6:10AM CST

PRGO: 154.25 (-0.21)

Perrigo to buy Omega Pharma
at Investor's Business Daily - Thu Nov 06, 5:49PM CST
The Ireland-based pharmaceuticals maker agreed to buy Belgium-based Omega Pharma for $4.5 bil, including debt, in a deal designed to expand Perrigo's (PRGO) presence in Europe. In its fiscal Q1, Perrigo earned $1.40 a share, missing views by 4 cents,...
PRGO: 154.25 (-0.21)

After Yesterday's Decline of 3.79%, Perrigo Offers Investors Better Value
Comtex SmarTrend(R) - Thu Nov 06, 3:41PM CST
Perrigo (NASDAQ RGO) traded in a range yesterday that spanned from a low of $145.41 to a high of $160.85. Yesterday, the shares fell 3.8%, which took the trading range below the 3-day low of $158.30 on volume of 4.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PRGO: 154.25 (-0.21)

Perrigo (PRGO) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Thu Nov 06, 3:39PM CST
The following Perrigo (PRGO) conference call took place on November 6, 2014, 10:00 AM ET. This is a transcript of that earnings call:
PRGO: 154.25 (-0.21)

Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 209.77 (+11.12), BIIB: 303.30 (-2.13), PRGO: 154.25 (-0.21), ABBV: 65.25 (+1.25)

Today's Market: Earnings And News Moving These 5 Stocks
Matthew Smith - at Seeking Alpha - Thu Nov 06, 9:01AM CST

TSLA: 253.18 (-5.50), PRGO: 154.25 (-0.21), QCOM: 70.67 (-0.18), AZN: 72.15 (-0.70), SNY: 47.43 (+0.75)

Perrigo buys consumer health products firm
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:44AM CST

PRGO: 154.25 (-0.21)

Perrigo Reinitiates Shipments Of Guaifenesin Extended-Release 600mg Tablets, The Store Brand Equivalent To Mucinex® 600mg Extended-Release Tablets
PR Newswire - Thu Nov 06, 5:39AM CST
Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex® 600mg Extended-Release tablets.
PRGO: 154.25 (-0.21)

Perrigo misses by $0.04, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 5:35AM CST

PRGO: 154.25 (-0.21)

Perrigo Company PLC Reports Record First Quarter Revenue, Adjusted Net Income And Adjusted Margins
PR Newswire - Thu Nov 06, 5:32AM CST
-- Fiscal first quarter net sales increased to a first quarter record of $952 million.
PRGO: 154.25 (-0.21)

Perrigo Company plc To Acquire Omega Pharma NV For EUR 3.6 Billion Creating A Top Five Global OTC Company
PR Newswire - Thu Nov 06, 5:26AM CST
Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," and Omega Pharma NV, one of the largest OTC healthcare companies in Europe, headquartered in Nazareth, Belgium, today announced that they have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for EUR 3.6 billion, or $4.5 billion, comprised of the purchase of Omega's equity for EUR 2.48 billion and the assumption of EUR 1.1 billion in debt. The transaction, funded through a combination of cash, debt, and equity, will enhance Perrigo's leading OTC product offering and expand its distribution through Omega's strong established platform.
PRGO: 154.25 (-0.21)

Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 107.56 (+0.66), ACT: 248.28 (+4.51), PRGO: 154.25 (-0.21), ALNY: 89.48 (-0.64)

Financial Results, Appointments, and Upcoming Conference Calls - Research Reports on Yelp, Vantiv, Discovery, Vistaprint and Perrigo
PR Newswire - Tue Nov 04, 7:55AM CST
Today, Analysts Review released its research reports regarding Yelp, Inc. (NYSE: YELP), Vantiv, Inc. (NYSE: VNTV), Discovery Communications, Inc. (NASDAQ: DISCA), Vistaprint N.V. (NASDAQ: VPRT) and Perrigo Company Plc (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7669-100free.
PRGO: 154.25 (-0.21), DISCA: 32.80 (-0.73), VPRT: 67.60 (+0.80), VNTV: 31.71 (+0.13), YELP: 58.80 (-1.02)

Perrigo declares $0.105 dividend
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 2:44PM CST

PRGO: 154.25 (-0.21)

Perrigo Company plc Announces Quarterly Dividend
PR Newswire - Mon Nov 03, 2:12PM CST
Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.105 per share, payable on December 16, 2014 to shareholders of record on November 28, 2014.
PRGO: 154.25 (-0.21)

Perrigo Rises 4.08% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Oct 30, 4:18PM CDT
Perrigo (NASDAQ RGO) traded in a range yesterday that spanned from a low of $153.00 to a high of $161.35. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $156.35 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PRGO: 154.25 (-0.21)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading